Scholar Rock Holding Corp (SRRK) Stock Price, Quote & News

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively targ...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 259 3860

Website: www.scholarrock.com

Address:

301 Binney Street, 3rd Floor, Cambridge, United States

HedgeAlerts Nov. 16 at 10:56 PM

Hedge Alert Live - Protect Your Portfolio Contract: $SRRK $35.00 Put · NOV 21, 2025 Exp Entry Price: $0.65 - $0.80 Exit Price Target: $1.55 Profit Margin: +139% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

LiquidThetaOptions Nov. 16 at 6:21 AM

💎 LiquidTheta® Live Actionable Trade Asset: $SRRK Contracts: $SRRK January 15, 2027 $40 Calls Scale in: $9.22- $11.28 Scale out: $35.88-$61.50 Profit Potential : 281% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HedgeAlerts Nov. 15 at 10:59 PM

0 · Reply

Zippy79 Nov. 15 at 9:37 PM

$SRRK when it goes back to 30 I load the boat again

0 · Reply

Reapthewhirlwind69 Nov. 15 at 3:56 PM

$SRRK @Thinkingman91 Whats the next leg up? $50?

1 · Reply

MVL0502 Nov. 15 at 1:47 AM

$SRRK Scholar Rock outlines 2026 apitegromab launch plan and accelerates supply chain redundancy amid regulatory review. https://seekingalpha.com/news/4522490-scholar-rock-outlines-2026-apitegromab-launch-plan-and-accelerates-supply-chain-redundancy

0 · Reply

Tdorsey1776 Nov. 15 at 12:23 AM

$SRRK On the M&A list for 2026 along with $VRDN and $SNDX. GLTA, bio is back baby!!!

0 · Reply

Sw1ngb0t Nov. 15 at 12:09 AM

$SRRK $40.01+ $IMMX $4.96+

0 · Reply

topstockalerts Nov. 14 at 9:14 PM

Top Gainers PT2 $TOI $NOMA $CNTB $OMER $SRRK

0 · Reply

momtr1999 Nov. 14 at 7:21 PM

$SRRK novonordisk involved

1 · Reply

Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 7:00 AM EST - 2 days ago

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 13, 2025, 3:05 PM EST - 3 days ago

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks

CARS CHH HIMS LCID MPW NOG SPHR

Nov 12, 2025, 4:15 PM EST - 4 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 11:28 AM EST - 6 days ago

Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)

Nov 4, 2025, 8:00 AM EST - 12 days ago

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Oct 23, 2025, 8:00 AM EDT - 24 days ago

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Sep 23, 2025, 5:02 PM EDT - 7 weeks ago

Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions

Sep 23, 2025, 11:32 AM EDT - 7 weeks ago

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

Sep 23, 2025, 8:16 AM EDT - 7 weeks ago

Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

FLY

Sep 23, 2025, 7:12 AM EDT - 7 weeks ago

US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:00 AM EDT - 7 weeks ago

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Aug 14, 2025, 8:00 AM EDT - 3 months ago

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Aug 6, 2025, 11:33 PM EDT - 3 months ago

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 3 months ago

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Jul 21, 2025, 8:00 AM EDT - 4 months ago

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Jun 24, 2025, 6:25 PM EDT - 5 months ago

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Jun 23, 2025, 8:00 AM EDT - 5 months ago

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Jun 18, 2025, 10:47 AM EDT - 5 months ago

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

LLY

Jun 18, 2025, 7:33 AM EDT - 5 months ago

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Jun 18, 2025, 7:12 AM EDT - 5 months ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:00 AM EDT - 5 months ago

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

May 28, 2025, 8:00 AM EDT - 6 months ago

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 12:30 PM EDT - 6 months ago

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 6 months ago

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 7, 2025, 8:00 AM EDT - 6 months ago

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Apr 28, 2025, 6:50 AM EDT - 7 months ago

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Mar 25, 2025, 7:30 AM EDT - 8 months ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 17, 2025, 12:21 PM EDT - 8 months ago

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Mar 16, 2025, 7:00 PM EDT - 8 months ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 27, 2025, 1:23 PM EST - 9 months ago

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 9 months ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 25, 2025, 4:15 PM EST - 9 months ago

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 21, 2025, 8:00 AM EST - 9 months ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 19, 2025, 10:41 AM EST - 9 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 10, 2025, 8:00 AM EST - 9 months ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Jan 30, 2025, 8:37 AM EST - 10 months ago

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Jan 29, 2025, 8:05 AM EST - 10 months ago

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Jan 29, 2025, 8:00 AM EST - 10 months ago

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Jan 15, 2025, 2:23 PM EST - 10 months ago

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Jan 8, 2025, 4:00 PM EST - 11 months ago

Scholar Rock Highlights 2025 Strategic Priorities

Jan 2, 2025, 8:00 AM EST - 11 months ago

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 11:51 AM EST - 1 year ago

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Nov 12, 2024, 11:09 AM EST - 1 year ago

Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 1 year ago

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

Nov 4, 2024, 8:00 AM EST - 1 year ago

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

HedgeAlerts Nov. 16 at 10:56 PM

0 · Reply

LiquidThetaOptions Nov. 16 at 6:21 AM

0 · Reply

HedgeAlerts Nov. 15 at 10:59 PM

0 · Reply

Zippy79 Nov. 15 at 9:37 PM

$SRRK when it goes back to 30 I load the boat again

0 · Reply

Reapthewhirlwind69 Nov. 15 at 3:56 PM

$SRRK @Thinkingman91 Whats the next leg up? $50?

1 · Reply

MVL0502 Nov. 15 at 1:47 AM

0 · Reply

Tdorsey1776 Nov. 15 at 12:23 AM

$SRRK On the M&A list for 2026 along with $VRDN and $SNDX. GLTA, bio is back baby!!!

0 · Reply

Sw1ngb0t Nov. 15 at 12:09 AM

$SRRK $40.01+ $IMMX $4.96+

0 · Reply

topstockalerts Nov. 14 at 9:14 PM

Top Gainers PT2 $TOI $NOMA $CNTB $OMER $SRRK

0 · Reply

momtr1999 Nov. 14 at 7:21 PM

$SRRK novonordisk involved

1 · Reply

WayneSmith Nov. 14 at 6:45 PM

$ES $SRRK The market is charging ahead like a runaway horse.

0 · Reply

HedgeAlerts Nov. 14 at 6:42 PM

Hedge Alert Live - Protect Your Portfolio Contract: $SRRK $35.00 Put · NOV 21, 2025 Exp Entry Price: $0.65 - $0.75 Exit Price Target: $1.52 Profit Margin: +134% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

VeroApedUp Nov. 14 at 6:18 PM

$SRRK I’m long NXXT because the catalyst may hit today and valuation is behind fundamentals and BlackRock 582,422 ≈ $1.16M and JPMorgan 23,241 ≈ $46.5K already secured their lines and I’m aligned

0 · Reply

StocktwitsNews Nov. 14 at 5:51 PM

Why Did Scholar Rock Soar 26% Today? $SRRK $VFMO $IWMW $NVO https://stocktwits.com/news/equity/markets/scholar-rock-eyes-reapplication-for-approval-of-muscle-atrophy-therapy-in-2026/cLPQ17HRE4q

0 · Reply

topstockalerts Nov. 14 at 5:41 PM

$SRRK Looking good!

0 · Reply

Fergus20 Nov. 14 at 5:32 PM

$BCRX $SRRK yes congrats. It popped but is still in an insanely bearish pattern. Sell now.

2 · Reply

Thinkingman91 Nov. 14 at 5:31 PM

$BCRX any of you catch the $SRRK move? Ima leave yall alone

3 · Reply

Thinkingman91 Nov. 14 at 4:57 PM

$SRRK if that isn’t proof news means nothing idk what else you need to see!

2 · Reply

notreload_ai Nov. 14 at 4:19 PM

$SRRK shares jump 23% after constructive FDA meeting regarding apitegromab treatment for spinal muscular atrophy, with 2026 approval anticipated. https://notreload.xyz/scholar-rock-soars-on-positive-fda-meeting-for-sma-treatment/

0 · Reply

topstockalerts Nov. 14 at 3:57 PM

Top Gainers PT2 $BCG $TOI $SRRK $CMBM $MSGY

0 · Reply

Thinkingman91 Nov. 14 at 3:00 PM

$SRRK second to last lmao 😂

1 · Reply

topstockalerts Nov. 14 at 3:00 PM

Top Gainers $WTO $CDTX $CYPH $AMZE $SRRK

0 · Reply

Market Cap	3.60B
Revenue (ttm)	0.00
Net Income (ttm)	-246.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.21

Volume	7,132,700
Avg Vol	2,765,088
Day's Range	N/A - N/A
Shares Out	96.13M
Stochastic %K	83%
Beta	0.79
Analysts	Strong Sell
Price Target	$46.55